drugset / Trial / NCT03505853

A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)

NCT03505853

Phase 1 Completed 10 enrolled Alnylam Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effect of givosiran on the pharmacokinetics of the 5-probe cocktail of midazolam, caffeine, losartan, omeprazole, and dextromethorphan, and their metabolites, in asymptomatic patients with Acute Intermittent Porphyria.

Timeline

Start
2018-04-26
Primary completion
2018-11-16
Completion
2019-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Caffeine Small molecule
Subject Dextromethorphan Unknown
Subject Givosiran Small interfering RNA (siRNA) Subcutaneous
Subject Losartan Other / unclassified
Subject Midazolam Small molecule
Subject Omeprazole Other / unclassified